HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival

被引：0
|
作者：
de Nonneville, Alexandre
Finetti, Pascal
Boudin, Laurys
Usclade, Lucas
Viens, Patrice
Viret, Frederic
Mamessier, Emilie
Goncalves, Anthony
Bertucci, Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-02-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-02-07
引用
收藏
页数：3
相关论文
共 50 条
  • [21] HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, F.
    Da Silva, A.
    Johnson, A. C.
    Fournier, C. Blanc
    Broyelle, A.
    Abramovici, O.
    Morel, A.
    Bertho, M.
    Hrab, I.
    Allouache, D.
    Djezzer, C. Segura
    Levy, C.
    Boscher, C.
    Villemin, M.
    Rottier, P.
    Lequesne, J.
    Emile, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S172 - S172
  • [22] Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers
    de Nonneville, Alexandre
    Houvenaeghel, Gilles
    Cohen, Monique
    Sabiani, Laura
    Bannier, Marie
    Viret, Frederic
    Goncalves, Anthony
    Bertucci, Francois
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 181 - 188
  • [23] Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers
    de Nonneville, Alexandre
    Houvenaeghel, Gilles
    Cohen, Monique
    Sabiani, Laura
    Bannier, Marie
    Viret, Frederic
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [25] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [26] Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis
    Liu, Mei
    Xiang, Qin
    Dai, Fengsheng
    Yuan, Yixiao
    Wu, Zhongjun
    Xiang, Tingxiu
    CLINICAL BREAST CANCER, 2024, 24 (07) : 575 - +
  • [27] The impact of the HER2-low status on conditional survival in patients with breast cancer
    Ma, Teng
    Liu, Changgen
    Ma, Tianyi
    Sun, Xinyi
    Cui, Jian
    Wang, Lulu
    Mao, Yan
    Wang, Haibo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [28] Overall survival in patients with HER2-low breast cancer at a reference hospital in Mexico
    Lorena Rubio-Anguiano, Brenda
    Valencia-Cedillo, Raquel
    Grajales, Rocio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer
    Sen, Gulin Alkan
    Aydin, Esra
    Guliyev, Murad
    Oztas, Nihan Senturk
    Degerli, Ezgi
    Demirci, Nebi Serkan
    Turna, Zeynep Hande
    Demirelli, Fuat Hulusi
    BMC CANCER, 2024, 24 (01)
  • [30] Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy
    Sartori, Guilherme
    Ramalho, Susana
    da Silva, Leonardo Roberto
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Vasconcelos, Vivian
    Mantovani, Higor
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Cabello, Cesar
    Barrios, Carlos
    Graudenz, Marcia Silveira
    CANCER RESEARCH, 2024, 84 (09)
12345